Expert Roundtable: Scale-up considerations for improved yield in upstream viral vector production

Cell & Gene Therapy Insights 2019; 5(12), 1719-1725.


Published: 17 February 2020
Expert Roundtable Video
S Ansorge, M Burnham, M Kelly et al.

Sven Ansorge

Director of Manufacturing at ExCellThera Inc.

Sven holds a PhD in Chemical Engineering and has led teams and managed projects within academic and industrial/GMP manufacturing environments. He is specialized in bioprocessing for the production of viral vectors, vaccines and recombinant proteins.

Mike Burnham

Director of the Vector Development department at Tmunity Therapeutics Inc.

Mike has over 25 years’ of biosafety and bioprocessing expertise, and is currently working to establish Tmunity’s lentiviral vector manufacturing platform. Prior to joining the team, Mike worked at WuXi AppTec, serving in multiple roles in their Process Development, Viral Production/Purification and Viral Clearance departments.

Michael Kelly

Vice President of Process Development at Avrobio

Avrobio is a clinical stage company developing gene therapies for rare diseases. Michael has over 20 years of experience in the field of gene therapy. During this time, Mike has been responsible for various aspects of research, development and clinical manufacturing for a number of lentiviral, adenoviral and AAV-based therapeutics.

Ruth McDermott

Segment Marketing Manager at Sartorius

Ruth has 20 years of business and market development experience within the life sciences industry, including roles in technology and IP commercialization. Ruth’s technical knowledge has been built on a background of R&D in cell bioprocessing, stem cells and gene therapy. Ruth holds a PhD in Cell Biology and an MBA.

Peter Jones

Head of Operational Strategy at Oxford Biomedica

Peter has over 30 years’ experience in the biopharmaceutical industry. He joined Oxford Biomedica in 2011, providing technical and scientific leadership. In his current role, he is responsible for overseeing strategic and operational planning to develop the Company’s capabilities and capacity to support future business growth. Peter is a Fellow of the Institution of Chemical Engineers and the Royal Academy of Engineering Visiting Professor in Manufacturing of Advanced Therapies at Aston University.